drugset
drugset / Trial / NCT06561087

Phase II Randomized, Placebo- Controlled Study of Intralesional Nivolumab for High-risk Oral Premalignant Lesions

NCT06561087 ↗

Phase 2 Recruiting 45 enrolled M.D. Anderson Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the antitumor efficacy of intralesional injections of nivolumab in patients with high-risk oral premalignant lesions

Timeline

Start
2025-02-27
Primary completion
2027-05-30
Completion
2029-05-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Nivolumab Monoclonal antibody — Other

Indications

preneoplastic lesion